Literature DB >> 28712945

Intestinal and Extraintestinal Cancers Associated With Inflammatory Bowel Disease.

Minna Chang1, Liisa Chang2, Hanna M Chang1, Fuju Chang3.   

Abstract

Inflammatory bowel disease (IBD) with its 2 most common entities, ulcerative colitis and Crohn's disease, causes an increased risk of developing intestinal cancers. In fact, malignancies are the second most common cause of death after cardiovascular diseases in both sexes of patients with IBD. Risk factors for colorectal cancer in IBD correlate with the duration of the disease, extent of disease, the association with primary sclerosing cholangitis, family history, and early age at onset. Patients with IBD also have an increased risk for developing a variety of extraintestinal malignancies. In particular, lymphomas, mostly non-Hodgkin lymphomas and skin cancers, are more frequently observed in IBD patients. Longstanding inflammation and the degree of immunosuppression as a result of IBD treatment appear to be the main driving factors for IBD-related carcinogenesis. This review provides an update on the clinical and pathological features of IBD-related intestinal and extraintestinal malignancies.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cholangiocarcinoma; Colorectal cancer; Crohn's disease; Dysplasia; Lymphoma; Ulcerative colitis

Mesh:

Year:  2017        PMID: 28712945     DOI: 10.1016/j.clcc.2017.06.009

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN: 1533-0028            Impact factor:   4.481


  12 in total

1.  Receipt of Preventive Care Services Among US Adults with Inflammatory Bowel Disease, 2015-2016.

Authors:  Fang Xu; James M Dahlhamer; Emily P Terlizzi; Anne G Wheaton; Janet B Croft
Journal:  Dig Dis Sci       Date:  2019-02-12       Impact factor: 3.487

2.  Antimicrobial peptide CC34 attenuates intestinal inflammation via downregulation of the NF-κB signaling pathway.

Authors:  Liqiang Dong; Huan Yang; Zhao Wang; Ning Jiang; Aizhong Zhang
Journal:  3 Biotech       Date:  2021-08-04       Impact factor: 2.893

3.  Cervical Cancer Screening in Inflammatory Bowel Disease: Who Should Be Screening?

Authors:  Anuj Chhaparia; Florence Odufalu; Mitchell Edwards; Krishna Patel; Kara Christopher; Katie Schroeder; Charlene Prather; Muhammad B Hammami
Journal:  Gastroenterology Res       Date:  2020-10-08

Review 4.  Cancer biologics made in plants.

Authors:  Matthew Dent; Nobuyuki Matoba
Journal:  Curr Opin Biotechnol       Date:  2019-11-27       Impact factor: 9.740

Review 5.  Inflammatory cell death in intestinal pathologies.

Authors:  Deepika Sharma; Thirumala-Devi Kanneganti
Journal:  Immunol Rev       Date:  2017-11       Impact factor: 12.988

6.  Evaluation of Monocarboxylate Transporter 4 in Inflammatory Bowel Disease and Its Potential Use as a Diagnostic Marker.

Authors:  Liying He; Hongli Wang; Yuhua Zhang; Lanlan Geng; Min Yang; Zhaohui Xu; Kejian Zou; Wanfu Xu; Sitang Gong
Journal:  Dis Markers       Date:  2018-05-08       Impact factor: 3.434

7.  Pleomorphic undifferentiated soft tissue sarcoma in patient with long standing inflammatory bowel disease.

Authors:  Loredana Labinac-Peteh; Robert Terlević; Božo Krušlin
Journal:  Autops Case Rep       Date:  2018-04-18

Review 8.  Molecular Pathogenesis of Cholangiocarcinoma.

Authors:  Peter L Labib; George Goodchild; Stephen P Pereira
Journal:  BMC Cancer       Date:  2019-02-28       Impact factor: 4.430

9.  BG-4 from Bitter Gourd (Momordica charantia) Differentially Affects Inflammation In Vitro and In Vivo.

Authors:  Andrea Nieto-Veloza; Zhihong Wang; Qixin Zhong; Hari B Krishnan; Vermont P Dia
Journal:  Antioxidants (Basel)       Date:  2019-06-14

10.  Casein Oligochitosan-Glycation by Transglutaminase Enhances the Anti-Inflammatory Potential of Casein Hydrolysates to the Lipopolysaccharide-Stimulated IEC-6 Cells.

Authors:  Na Chen; Li Wang; Qiang Zhang; Xin-Huai Zhao; Jia Shi
Journal:  Nutrients       Date:  2022-02-06       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.